AVEO Pharmaceuticals Inc. (AVEO)

0.61
0.00 0.11
NASDAQ : Health Technology
Prev Close 0.61
Open 0.62
Day Low/High 0.60 / 0.63
52 Wk Low/High 0.56 / 3.59
Volume 2.45M
Avg Volume 3.58M
Exchange NASDAQ
Shares Outstanding 125.35M
Market Cap 82.02M
P/E Ratio N/A
Div & Yield N.A. (N.A)
AVEO Announces Strategic Restructuring And Provides Third Quarter Financial Results

AVEO Announces Strategic Restructuring And Provides Third Quarter Financial Results

AVEO Oncology (NASDAQ: AVEO) today announced a strategic restructuring designed to optimize resources and reduce expenses to ensure AVEO is well positioned for a successful launch of tivozanib in renal cell carcinoma...

AVEO Oncology Announces Timing For Third Quarter Financial Results, Webcast And Conference Call

AVEO Oncology Announces Timing For Third Quarter Financial Results, Webcast And Conference Call

AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s third quarter ended September 30, 2012 will be released before the market opens on Tuesday, October 30, 2012.

AVEO And Astellas Announce New Data Presented At ESMO 2012 Congress Demonstrating The Safety And Tolerability Profile Of Tivozanib In Patients With Advanced Kidney Cancer

AVEO And Astellas Announce New Data Presented At ESMO 2012 Congress Demonstrating The Safety And Tolerability Profile Of Tivozanib In Patients With Advanced Kidney Cancer

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced new data from the Phase 3 TIVO-1 trial ( TIvozanib Versus s Orafenib in 1 st line advanced RCC) demonstrating the safety and...

AVEO Announces Detailed Results Of Exploratory Phase 2 Study Evaluating Ficlatuzumab In First-Line Patients With Advanced Non-small Cell Lung Cancer; New Data Presented At ESMO

AVEO Announces Detailed Results Of Exploratory Phase 2 Study Evaluating Ficlatuzumab In First-Line Patients With Advanced Non-small Cell Lung Cancer; New Data Presented At ESMO

AVEO Oncology (NASDAQ: AVEO) today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company’s HGF inhibitory antibody, and gefitinib ...

AVEO And Astellas Announce Submission Of New Drug Application For Tivozanib For The Treatment Of Advanced Renal Cell Carcinoma

AVEO And Astellas Announce Submission Of New Drug Application For Tivozanib For The Treatment Of Advanced Renal Cell Carcinoma

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE:4503) today announced that AVEO has submitted a New Drug Application (NDA) to the U.

New Clinical Data On AVEO Oncology’s Tivozanib And Ficlatuzumab To Be Presented At The ESMO 2012 Congress

New Clinical Data On AVEO Oncology’s Tivozanib And Ficlatuzumab To Be Presented At The ESMO 2012 Congress

AVEO Oncology (NASDAQ: AVEO) today announced that new clinical data on its lead product candidate tivozanib, partnered with Astellas Pharma Inc.

AVEO Oncology To Present At The UBS Annual Global Life Sciences Conference

AVEO Oncology To Present At The UBS Annual Global Life Sciences Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the UBS Annual Global Life Sciences Conference on Thursday, September 20, 2012 at 2:00 p.

AVEO Oncology To Present At The Morgan Stanley Global Healthcare Conference

AVEO Oncology To Present At The Morgan Stanley Global Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Monday, September 10, 2012 at 10:35 a.

AVEO Oncology To Present At The Canaccord Genuity 32nd Annual Growth Conference

AVEO Oncology To Present At The Canaccord Genuity 32nd Annual Growth Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Canaccord Genuity 32 nd Annual Growth Conference on Thursday, August 16, 2012 at 10:00 a.

AVEO Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

AVEO Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

AVEO Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

AVEO Reports Second Quarter 2012 Financial Results

AVEO Reports Second Quarter 2012 Financial Results

AVEO Oncology (NASDAQ: AVEO) today reported consolidated financial results for the second quarter of 2012, and highlighted recent developments and key second quarter accomplishments.

AVEO Oncology Announces Timing For Second Quarter Financial Results, Webcast And Conference Call

AVEO Oncology Announces Timing For Second Quarter Financial Results, Webcast And Conference Call

AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company's second quarter ended June 30, 2012 will be released before the market opens on Thursday, August 2, 2012.

AVEO And Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib With Sunitinib In First-Line Kidney Cancer

AVEO And Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib With Sunitinib In First-Line Kidney Cancer

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced plans to initiate a new clinical study, TAURUS ( Tivoz Anib Use ve Rs Us Sutent in advanced renal cell carcinoma (RCC): Patient...

ASCO '12 Stocks: Winners and Losers

ASCO '12 Stocks: Winners and Losers

Snap judgments in biotech and drug stocks after a weekend spent at the ASCO cancer meeting.

ASCO 2012 Live Blog -- Saturday

ASCO 2012 Live Blog -- Saturday

TheStreet's biotech columnist Adam Feuerstein brings you live coverage of ASCO, the Super Bowl of cancer drug medical conferences.

AVEO Oncology To Host Conference Call And Webcast To Review Phase 3 TIVO-1 Data Presented At ASCO

AVEO Oncology To Host Conference Call And Webcast To Review Phase 3 TIVO-1 Data Presented At ASCO

AVEO Oncology (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Monday, June 4, 2012 at 7:30 a.

AVEO Oncology To Present At The Jefferies 2012 Global Healthcare Conference

AVEO Oncology To Present At The Jefferies 2012 Global Healthcare Conference

AVEO Oncology (Nasdaq: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5, 2012 at 3:00 p.

AVEO Initiates Phase 1 Study Of AV-203, An ERBB3 Inhibitory Antibody, In Advanced Solid Tumors

AVEO Initiates Phase 1 Study Of AV-203, An ERBB3 Inhibitory Antibody, In Advanced Solid Tumors

AVEO Oncology (Nasdaq: AVEO) today announced the initiation of a Phase 1 study examining the safety and preliminary efficacy of AV-203 along with exploratory biomarkers in patients with advanced solid tumors.

AVEO Stock Falls On Unusually High Volume (AVEO)

AVEO Stock Falls On Unusually High Volume (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) is trading at unusually high volume Thursday with 1.4 million shares changing hands. It is currently at four times its average daily volume and trading down 70 cents (-5.6%).

ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update)

ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update)

Array Biopharma, Exelixis,Onyx Pharma and Pharmacyclics among cancer drug developers releasing new data ahead of the big ASCO meeting.

AVEO And Astellas Announce Positive Findings From TIVO-1 Superiority Study Of Tivozanib In First-Line Advanced RCC

AVEO And Astellas Announce Positive Findings From TIVO-1 Superiority Study Of Tivozanib In First-Line Advanced RCC

AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced that detailed data from TIVO-1 ( Tivozanib Versus S orafenib in 1 st line Advanced RCC), will be presented on June 2 in an oral...

ASCO '12 Abstract Dump: Cancer Stocks in Focus

ASCO '12 Abstract Dump: Cancer Stocks in Focus

Array Biopharma, Exelixis, Aveo and Pharmacyclics among cancer drug developers releasing new data ahead of the big ASCO meeting.

AVEO Reports First Quarter 2012 Financial Results And Recent Developments

AVEO Reports First Quarter 2012 Financial Results And Recent Developments

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported consolidated financial results for the first quarter of 2012 and reviewed key first quarter accomplishments.

AVEO Announces Preliminary Results Of Exploratory Phase 2 Study Evaluating HGF Inhibitor In First-Line Patients With Advanced Lung Cancer

AVEO Announces Preliminary Results Of Exploratory Phase 2 Study Evaluating HGF Inhibitor In First-Line Patients With Advanced Lung Cancer

AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) announced today preliminary data from the exploratory, randomized Phase 2 study comparing the combination of ficlatuzumab and gefitinib, an EGFR tyrosine kinase inhibitor (TKI),...

AVEO Pharmaceuticals, Inc. To Present At Upcoming Investment Conferences

AVEO Pharmaceuticals, Inc. To Present At Upcoming Investment Conferences

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that the company’s management will present a company overview at upcoming investment conferences.

Biotech Stock Mailbag: AVI, Aveo, Spectrum

Biotech Stock Mailbag: AVI, Aveo, Spectrum

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

AVEO Pharmaceuticals, Inc. Announces Timing For First Quarter Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. Announces Timing For First Quarter Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company's first quarter ended March 31, 2012 will be released before the market opens on Thursday, May 3, 2012.

AVEO Announces Publication Of Positive Tivozanib Phase 2 Clinical Trial Results In Journal Of Clinical Oncology

AVEO Announces Publication Of Positive Tivozanib Phase 2 Clinical Trial Results In Journal Of Clinical Oncology

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported results from a successful Phase 2 clinical trial evaluating the efficacy and safety of tivozanib in 272 patients with advanced renal ...

AVEO Stock Hits New 52-Week Low (AVEO)

AVEO Stock Hits New 52-Week Low (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) hit a new 52-week low Wednesday as it is currently trading at $11.22, below its previous 52-week low of $11.28 with 36,912 shares traded as of 10:10 a.m. ET. Average volume has been 272,200 shares over the past 30 days.

AVEO Pharmaceuticals Inc. Stock Downgraded (AVEO)

AVEO Pharmaceuticals Inc. Stock Downgraded (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) has been downgraded by TheStreet Ratings from from a hold to sell.

TheStreet Quant Rating: D- (Sell)